Penumbra, Inc. (PEN) Revenue by Segment

Executive TeamFinancialsSegments
Shareholders

Penumbra revenue by segment at a glance

In Q2 fiscal 2026 (the quarter ended June 30, 2026), Penumbra's largest product or service was Thrombectomy, with $258.98 million or 66% of revenue, up 12.5% from a year earlier. Next: Embolization and Access (34%).

By region, United States brought in 78% and Non-US brought in 22% of revenue in Q2 fiscal 2026.

By country, UNITED STATES brought in 78% and Non-US brought in 22% of revenue in Q2 fiscal 2026.

The fastest-growing product or service from a year earlier was Embolization and Access (+20.0%).

From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.

PEN logo

Penumbra, Inc.

PENUnited States
Healthcare

Revenue breakdown

Fiscal quarters, from company filings

Penumbra revenue by product or service, last 4 quarters

Product or serviceQ2 FY26Q1 FY26Q3 FY25Q2 FY25Share
Thrombectomy$259.0M$253.9M$236.4M$230.3M66%
Embolization and Access$131.1M$120.8M$118.3M$109.2M34%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Penumbra revenue by region, last 4 quarters

RegionQ2 FY26Q1 FY26Q3 FY25Q2 FY25Share
United States$305.4M$296.4M$275.0M$260.8M78%
Non-US$84.6M$78.4M–$78.6M22%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Penumbra revenue by country, last 4 quarters

CountryQ2 FY26Q1 FY26Q3 FY25Q2 FY25Share
UNITED STATES$305.4M$296.4M$275.0M$260.8M78%
Non-US$84.6M$78.4M–$78.6M22%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Questions and answers

Which product or service makes the most money for Penumbra?

Thrombectomy: $258.98 million, or 66% of revenue, in Q2 fiscal 2026.

What are Penumbra's main products and services?

By revenue in Q2 fiscal 2026: Thrombectomy (66%) and Embolization and Access (34%).

Where does Penumbra make its money?

By region in Q2 fiscal 2026: United States (78%) and Non-US (22%).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube